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Abstract
Background Diabetes mellitus, as well as subsequent ocular
complications such as cystoid macular edema (CME), are
of fundametal socio-economic relevance. Therefore, we
evaluated the influence of internal limiting membrane
(ILM) removal on longterm morphological and functional
outcome in patients with diabetes mellitus (DM) type 2 and
chronic CME without evident vitreomacular traction.
Method Forty eyes with attached posterior hyaloid were
included in this prospective trial and randomized intraoper-
atively. Prior focal (n=31) or panretinal (n=25) laser
coagulationwas permitted. Group I (n=19 patients) underwent
surgical induction of posterior vitreous detachment (PVD),
group II (n=20 patients) PVD and removal of the ILM.
Eleven patients with detached posterior hyaloid (group III)
were not randomized, and ILM removal was performed. One
eye had to be excluded from further analysis. Examinations
included ETDRS best-corrected visual acuity (BCVA),
fluorescein angiography (FLA) and OCT at baseline, 3 and
6 months postoperatively. Main outcome measure was BCVA
at 6 months, secondary was foveal thickness.
Results Mean BCVA over 6 months remained unchanged
in 85% of patients of group II, and decreased in 53% of
patients of group I. Results were not statistically significant
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different [group I: mean decrease log MAR 95% CI (0.06;
0.32), group II: (−0.02; 0.11)]. OCT revealed a significantly
greater reduction of foveal thickness following PVD with
ILM removal [group I: mean change: 95% CI (−208.95 μm;
−78.05 μm), group II: (−80.90 μm: +59.17 μm)].
Conclusion Vitrectomy, PVD with or without ILM removal
does not improve vision in patients with DM type 2 and
cystoid diabetic macular edema without evident vitreoretinal
traction. ILM delamination shows improved morphological
results, and appears to be beneficial in eyes with preexisting
PVD.
Keywords Vitrectomy . Posterior vitreous detachment .
Internal limiting membrane . Optical coherence
tomography . Cystoid diabetic macular edema
Introduction
In former investigations the vitreous and the vitreoretinal
junction have been detected as a modulator of diabetic
macular edema [1–7], and their precise role in the
pathogenesis of diabetic maculopathy is widely debated
[8]. Encouraged by reports showing that diabetic patients
with posterior vitreous detachment (PVD) are less likely to
develop macular edema [6] and that resorption may occur
after a spontaneous PVD [2, 9], vitrectomy with removal of
the posterior hyaloid was considered to be a therapeutic
option in diffuse and cystoid edema, which often persists
despite multiple laser treatments [5, 7, 10]. Lewis reported
successful vitrectomy in selected patients with diabetic
macular edema associated with visible posterior hyaloidal
traction [5]. Furthermore, clinical improvement has been
reported in eyes even when macular traction was stated to
be absent [4, 11–15]. Tachi and Ogino reported on a
prospective series of 58 eyes from 41 patients with visual
acuity improvement in 53% of cases. However, they
performed a combined cataract extraction in most of them
[13]. Several authors postulated a positive effect of
additional peeling of the internal limiting membrane
[ILM] in patients with diabetic macular edema refractory
to laser photocoagulation [1, 16–18]. Most reliable data on
the efficacy of vitrectomy and PVD was published by Otani
and Kishi and Stolba and coworkers, first reported on a
non-randomized series of seven patients after unilateral
vitrectomy with PVD and significant reduction of macular
edema in comparison with the fellow eye [12]. Stolba et al.
recently demonstrated in a prospective randomized trial that
vitrectomy with ILM removal provides better visual and
morphological results than the natural course [19].
Uncertainty remains as to whether vitrectomy and PVD alone
is sufficient, or whether additional ILM delamination is
beneficial. A prospective non-randomized study by Patel
et al. indicated that ILM removal achieves an improved
morphological outcome [20]. Gandorfer et al. showed a
remarkable decrease of macular edema, with improvement
of BCVA [1]. However, in most studies a reduction of
macular edema did not consequently lead to a better visual
acuity [3, 11].
Aim of this prospective randomized study was to
evaluate the efficacy of surgical PVD and additional ILM
removal in comparison to vitrectomy and PVD alone in
typical diabetes mellitus type 2 patients with cystoid
diabetic macular edema (CME) and without evident
vitreomacular traction.
Due to the ILM removal, human material became
available and was used to study sequestered factors, which
could be involved in the pathogenesis of early diabetic
retinopathy [21]. A further aim of the study was therefore to
look for factors in the ILM possibly inducing vascular
permeability changes.
Methods
Demographic data
The prospective randomized study population consisted of
50 patients (22 female, 28 male; 19 right eyes, 32 left eyes).
Pars plana vitrectomies were performed at the Department
of Ophthalmology, University Clinics Schleswig-Holstein,
Campus Luebeck for cystoid diabetic macular edema
between July 1999 and June 2003. Patients were divided
into three groups: group I: surgical PVD, group II: surgical
PVD and ILM removal, group III: preexisting PVD,
vitrectomy and ILM removal. One eye of group I was
excluded from further analyses because both eyes of one
single patient had been randomized. Thirty eyes presented
non-proliferative diabetic retinopathy (NPDRP) (group I:
73.68%; group II: 60%, group III: 36.36%) and 20 eyes
proliferative diabetic retinopathy (PDRP) (group I: 26.32%;
group II: 40%; group III: 63.64%). Nine out of these
revealed active but mild neovascularizations of the disc or
elsewhere; the others were quiescent. No fibrovascular
tissue or traction was present. None of the patients showed
a taut thickening of the posterior vitreous hyaloid by
biomicroscopy, neither preoperatively, nor intraoperatively.
Hard exudates in the macular region were present in 38
patients (76%). None of the patients revealed an enlarged
foveolar avascular zone on fluorescein angiography (FA). A
detachment of the neurosensory retina from the retinal
pigment epithelium or any sign of epiretinal membrane or
vitreoretinal traction was ruled out by biomicroscopy and
by optical coherence tomography (OCT).
At baseline, systemic hypertension controlled with
medications was present in 12/19 patients in group I, 15/
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20 patients in group II and 11/11 patients in group III.
Insulin-dependent diabetes mellitus was present in 13/19
patients in group I, 15/20 patients in group II and 9/11
patients in group III. Mean HbA1c levels were 7.59 in group
I, 8.15 in group II and 7.85 in group III. The demographic
data for each group are listed in Table 1.
Informed written consent was obtained for all patients,
and the study protocol was approved by the local ethics
committee.
Study protocol
The eligibility criteria for this study included cystoid
macular edema unresponsive to one or more laser treat-
ments (interval at least 3 months since last photocoagula-
tion). Only patients with diabetes mellitus type 2 were
enrolled in the study. Eyes with evident vitreomacular
traction, macular non-perfusion spreading over an area of
2 disc diameters, optic atrophy, subfoveal plaques or
vitreous hemorrhage were excluded, as well as eyes with
dense cataract or other ocular diseases. Vitreomacular
traction or epiretinal membranes were excluded by OCT.
The main outcome measure was BCVA determined by
ETDRS charts after 6 months. Secondary endpoint was
foveal thickness measured by OCT after 6 months.
Intraoperatively, after a preexisting PVD was ruled out,
the patient was either randomized to group I (surgical PVD
only) or group II (surgical PVD and ILM removal). In all of
them, a detachment of the posterior hyaloid was surgically
induced. An additional ILM delamination was performed in
group II. In 11 patients, the posterior hyaloid was intra-
operatively found not to be attached to the retina, as had
been presumed preoperatively. These eyes (22%) were not
randomized, but underwent ILM removal, and were
followed by the regular examination regimen to evaluate
the effect of ILM removal alone in patients with cystoid
diabetic macular edema and preexisting PVD. They were
summarized in group III. The participant flow chart
according to the CONSORT statement [22] is shown in
Fig. 1.
Examinations
Preoperatively and at 3 and 6 months postoperatively, all
eyes underwent ETDRS visual acuity testing, a careful
biomicroscopic evaluation, measurement of the foveal area
thickness using optical coherence tomography (OCT II and
III, Zeiss–Humphrey, Jena, Germany) and fluorescein
angiography. All regular examinations were performed by
the same examiner (MM). The visual acuity was evaluated
following the guidelines of the study protocol of the "Early
Treatment Diabetic Retinopathy Study Research Group"
(ETDRS) [23]. The postoperative visual outcomes of the
treatment groups were compared at 3 and 6 months.
Macular edema at baseline and during the follow-up was
assessed by fluorescein angiography in terms of size and
Table 1 Demographic data and patients characteristics at baseline in the treatment groups
Characteristics Group I (PVD) Group II (PVD+ILM-peeling) Group III (ILM-peeling)
Number of patients 19 20 11
Gender (n): male/female 10/9 12/8 6/5
Mean age (years) 66.0 (SD 8.96) 63.55 (SD 7.14) 70.0 (SD 6.23)
Preop. visual acuity (logMAR, mean) 0.59 (SD 0.23) 0.59 (SD 0.23) 0.65 (SD 0.27)
Preoperative foveal thickness (μm, mean) 425.25 (SD 83.25) 442.13 (SD 83.73) 478.9 (SD 134.86)
Lens-status (n):
- phakic 17 19 8
- pseudophakic 2 1 3
Type of diabetic retinopathy (n):
- non-proliferative 14 (73.63%) 12 (60%) 4 (36.36%)
- proliferative 5 (26.32%) 8 (40%) 7 (63.64%)
Prior laser treatment (n):
- panretinal 7 9 9
- focal/grid 16 15 10
Hypertension (n) 12 15 11
HbA1c level (%, mean) 7.59 (SD 1.17) 8.15 (SD 1.60) 7.85 (SD 1.24)
Serum creatine level (μmol/l, mean) 78.33 (SD 28.10) 78.00 (SD 20.84) 108.00 (SD 41.15)
Mean duration of diabetes mellitus (years, mean) 14.75 (SD 6.56) 12.67 (SD 5.40) 16.56 (SD 9.55)
Mean duration of macular edema (months, mean) 10.40 (SD 8.32) 10.29 (SD 7.14) 22.22 (SD 20.20)
Insulin dependent/non-insulin dependent (n) 13/6 15/5 9/2
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intensity, and by OCT measurements to determine the
foveal thickness, which was defined as the distance
between the inner retinal surface and the retinal pigment
epithelium at the central fovea. The fovea was scanned in
a vertical direction.
To analyze the long-term outcome within this prospective
study and to minimize the influence of cataract formation, we
decided to perform a late follow-up examination of the
patients, including BCVA and foveal thickness in addition to
the study protocol. Long-term visual acuity values were
obtained in part at our institution (ETDRS-VA) and in part by
the referring ophthalmologists (Snellen VA). Longterm OCT
thickness measurements could be obtained only in patients
who were re-examined in our institution. Results are analyzed
non-confirmatively.
Surgical procedure
After written informed consent was obtained, all operations
were performed by a single surgeon (HH) under general
anaesthesia. A three-port pars plana vitrectomy was
performed, and following core vitrectomy the posterior
vitreous cortex was detached from the retina by suction
over the optic nerve disc until the Weiss ring was identified.
No triamcinolone was used for this manoeuver, in order to
exclude a possible influence on the visual or morphological
outcome.
In patients randomized to group II and in patients of
group III, the ILM was removed using endgripping forceps.
The first 12 patients (nine of group II and three patients of
group III) underwent ILM removal without the use of dyes;
in the subsequent 19 patients (eleven of group II and eight
patients of group III) the ILM was stained with approxi-
mately 0.1 ml of indocyanine green (ICG-Pulsion, Munich,
Germany) dissolved in 5% glucose in a concentration of
0.05% under constant irrigation with Ringer's solution.
Immediately after application, dye remnants within the
vitreous cavity or outside the central retina were washed out
by suction using a flute needle or the ocutome. The ILM
removal was extended over the whole edematous area to
the vascular arcades, and was performed successfully in all
eyes. The removed tissue was confirmed to be ILM by light
microscopy, and in part further examined by immunohisto-
chemistry. Intraoperatively, panretinal argon endolaser
coagulation was performed in 11 of the 50 eyes (group I:
three eyes, group II: five eyes, group III: three eyes) for the
treatment of severe non-proliferative (n=2) or proliferative
diabetic retinopathy (n=9). No focal or grid laser therapy
was applied intraoperatively or within the follow-up period.
Then, a careful examination of the retinal periphery by
scleral indentation was carried out. Cryocoagulation was
performed for peripheral iatrogenic tears (n=10; group I:
three eyes, group II: five eyes, group III: two eyes). No
endotamponade was intended, but was necessary for
peripheral tears in ten eyes (gas: n=4, air: n=6).
Statistical analysis
Statistical analysis was performed using SAS (the SAS
System; Release 9.1.3 SP 2; SAS Institute Inc., Cary, NC,
USA) on Windows® 2000 SP 4 (Microsoft Corp., Redmond,
WA, USA). Values are given as frequency and percentage for
qualitative, and mean and standard deviation for quantitative
parameters respectively. 95% confidence intervals were
calculated using SAS PROC MEANS. Analyses of variance
(with repeated measures for time: preoperatively and at 3 and
6 months) were performed to evaluate time and treatment
effects on visual acuity (logMAR) and foveal thickness (OCT).
Immunhistochemistry of surgically excised ILM
Surgically removed ILM specimens of 24 patients were
examined by immunhistochemistry. Twelve specimens
were from patients of group II from our study, and 12 from
idiopathic macular holes without diabetes mellitus served as
control. The specimen were fixed in 4% buffered formalin
and embedded in paraffin. Eight-micrometer (8 μm)-thick
paraffin sections were cut and mounted onto silanized
Fig. 1 Participant flow chart for each treatment group. PVD=
posterior vitreous detachment, ILM=internal limiting membrane,
* two eyes of one single patient were randomized
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slides. ABC staining technique (Vector Laboratories/Linaris,
PK-6200, Wertheim-Bettingen, Germany) was used. Slides
were blocked in normal horse serum for 30 minutes at room
temperature (RT). Primary antibodies were mouse monoclonal
bFGF (Calbiochem, GF22, 1:100, Darmstadt, Germany), CML
(Novo Nordisk, 2F8, 1:1000, Malmö, Sweden), methylglyoxal
advanced glycation endproduct (AGE) antibody (Dr. M.
Brownlee, Albert Einstein Institute of Medicine, New York,
NY, USA, 1:500), tumor necrosis factor (TNF) alpha (Calbio-
chem, CN 654300, 1:100, Darmstadt, Germany), VEGF
(Calbiochem, GF-25, 1:20, Darmstadt, Germany), platelet-
derived growth factor (PDGF)-B (Santa Cruz, sc-7878, 1:500,
Heidelberg, Germany), and a goat polyclonal interleucin
(IL)-6 (Santa Cruz, sc-1266, 1:100, Heidelberg, Germany).
The slides were incubated for 1 hour at room temperature.
After three washing steps for 5 minutes in PBS, the sections
were incubated with the biotinylated secondary antibody
(ABC Kit) for 1 hour at room temperature, followed by a
second washing step. DAB as substrate was used for
detection. Photos were taken by Leica digital camera and IM
50 software.
Results
Visual acuity
Group I After vitrectomy, mean BCVA in group I
decreased from 20/80 (logMAR mean 0.59,
SD 0.23) preoperatively to 20/100 (logMAR
mean 0.70, SD 0.28) at 3 months and 20/125
(logMAR mean 0.78, SD 0.34) at 6 months.
BCVA improved more than 2 lines in one of 19
eyes (5.3%), remained the same in nine eyes
(47.4%) and worsened in nine eyes (47.4%).
Group II After vitrectomy, PVD and additional ILM
delamination, mean BCVA (preoperatively 20/
80 (logMAR mean 0.59, SD 0.23)) decreased to
20/100 (logMAR mean 0.65, SD 0.28) at
3 months and 20/100 (logMAR mean 0.64,
SD 0.21) at 6 months. BCVA improved more
than 2 lines in one of 20 eyes (5%), remained
the same in 17 eyes (85%) and decreased in two
eyes (10%).Comparing groups I and II, the
functional outcome did not reveal a signifi-
cant treatment effect, taking into account the
repeated measures (p=0.5492), but did show a
significant time effect (p=0.0040): at 6 months,
group I: mean decrease 0.19 logMAR, SD
0.27, 95% CI [0.06; 0.32], group II: mean
decrease 0.05 logMAR, SD 0.14, 95% CI
[−0.02; 0.11]).
Group III In group III, patients having preexisting PVD,
the mean preoperative BCVA was 20/100
(logMAR mean 0.65, SD 0.27). The mean
postoperative BCVA after vitrectomy and ILM
removal was unchanged at 20/100 (logMAR
mean 0.68, SD 0.28) at 3 months, and increased
to 20/80 (logMAR mean 0.60, SD 0.29) at
6 months postoperatively. BCVA improved
more than 2 lines in three of 11 eyes (27.3%),
remained the same in six eyes (54.5%) and
worsened in two eyes (18.2%). Since this group
was not randomized, no confirmative comparison
with the other groups was performed.
The functional results are presented in Fig. 2.
Foveal thickness measurement
Group I In patients of group I, mean preoperative foveal
thickness was 425.25 μm (SD 83.25 μm). Three
months postoperatively, the mean foveal thickness
in group I was 432.33 μm (SD 77.26 μm), and at
3 months 415.2μm (SD 132.25μm). There was no
significant effect of time (p=0.9198).
Group II In patients of group II, mean preoperative foveal
thickness was 442.13 μm (SD 83.73 μm). Three
months postoperatively, the foveal thickness in
group II decreased to a mean of 352.62 μm (SD
102.38 μm). Six months postoperatively, it
Fig. 2 Functional results of all groups, showing a decrease of best-
corrected visual acuity (BCVA) in group I with PVD only and stable
BCVA in groups II and III with additional ILM removal. The
influence of cataract progression has to be considered within the 6-
month follow-up period. Late follow-up BCVA values could be
obtained only in part at our institution. PVD=posterior vitreous
detachment, ILM=internal limiting membrane
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further decreased to a mean of 297.64 μm (SD
139.92). This group showed a significant effect of
time (p=0.0034). Comparing groups I and II, no
significant treatment effect was detected (p=
0.0871). However, in group II with ILM removal,
an increased resolution of edema was found at
3 months [mean difference to preoperative value
−93.92 μm, SD 122.28 μm, 95% CI: (−167.81;
−20.03) compared to a mean difference of
−7.42 μm, SD 62.43 μm; 95% CI: (−47.08;
32.25) in group I] and at 6 months [mean
difference −143.50 μm, SD 113.36 μm, 95% CI:
(−208.95; −78.05) compared to −10.87 μm, SD
126.47 μm, 95% CI: (−80.90; 59.17) in group I].
Group III In group III patients having preexisting PVD, the
preoperativemean foveal thickness was 478.90μm
(SD 134.86 μm). Three months after vitrectomy
and ILM removal the foveal thickness decreased to
a mean of 308.13 μm (SD 121.20 μm), and after
6 months to 296.60 μm (SD 121.42 μm). As this
group has not been randomized, no comparison
with other groups was performed.
The anatomic results of all groups measured by OCT are
presented in Fig 3.
Late follow-up-examination
Group I At a mean late follow-up of 56.01 months (SD
10.0 months) the functional data of 17 patients
were available. Despite cataract extraction that had
been performed in 13/16 phakic patients, mean
BCVA remained unchanged at 20/100 (logMAR
mean 0.72, SD 0.45), but mean foveal thickness of
eight patients at 54.01 months (SD 8.0 months)
further decreased to 357.0 μm (SD 95.09 μm).
Group II At a mean late follow-up of 46.0 months (SD
17.0 months), cataract extraction had been per-
formed in 13/19 phakic patients. BCVA of 17
patients at that time had decreased again to 20/63
(logMAR mean 0.47, SD 0.3). Correspondingly,
mean foveal thickness of 12 patients measured at
49.0 months (SD 5.0 months) had slightly
increased to 258.0 μm (SD 96.50). Comparing
the randomized treatment groups I and II at their
late follow-up visit, the functional outcome in
group II was favourable [group I: logMAR mean
0.16, SD 0.39, 95% CI: (−0.05; 0.36) group II:
logMAR mean −0,09, SD 0,32, 95% CI: (−0.25;
0.08)], but it has to be considered that only 17
patients of each of groups I and II were analyzed
and in part the visual acuity values were obtained
by the referring ophthalmologists (Snellen VA).
The morphological outcome at the late follow-up
visit again was favourable in group II: [group I:
mean difference −65.43 μm, SD 124.63 μm, 95%
CI: (−180.69;49.83), group II: −184.11 μm, SD
141.78μm, 95%CI: (−293.09;−75.13)], but only in
eight patients of group I and in 12 patients of group
II an OCT measurement could be obtained. The
mean decrease of foveal thickness in group II was
37.37% at the late visit [SD 24.82, 95% CI: (18.29,
56.45)], whereas in group I it was 13.53% at the late
visit [SD 27.18, 95% CI: (−11.61; 38.67)].
Group III At the late follow-up visit at 48.0 months (SD
16.00) postoperatively, cataract extraction had
been performed in all phakic patients (n=8).
BCVA of eight patients at that time was 20/100
(logMAR mean 0.65, SD 0.43). The mean
foveal thickness measured only in three patients
at 49.0 months (SD 8.00) was 354.67 μm (SD
223.04 μm; single values: 235.0 μm, 217.0 μm,
612.0 μm). The mean decrease was 28.92%
[SD22.45, 95% CI: (−26.84, 84.68)].
Subgroup analysis — indocyanine green
The first nine patients of group II and three patients of
group III underwent ILM removal without the use of dyes.
In 19 consecutive patients (11 of group II and eight of
group III), an ICG-assisted peeling of the ILM was
Fig. 3 Mean foveal thickness of treatment groups over the follow-up
period, showing only a slight decrease of edema in group I and
markedly better reabsorption in groups II and III with additional ILM
removal. Late follow-up OCT values could be obtained only in some
of the patients
1002 Graefes Arch Clin Exp Ophthalmol (2011) 249:997–1008
performed. Mean BCVA in the ICG group decreased
slightly from 20/80 [logMAR 0.59, SD 0.19, 95% CI:
(0.5; 0.68)] preoperatively to 20/80 [logMAR 0.61,SD
0.21, 95% CI: (0.5; 0.71)] at 6 months and remained stable
at the follow-up. Mean BCVA in the group without the use
of ICG decreased from 20/80 [logMAR 0.64, SD 0.19, 95%
CI: (0.44; 0.84)] preoperatively to 20/100 [logMAR 0.65,
SD 0.28, 95% CI: (0.47; 0.83)] at 6 months, and increased
to 20/50 [logMAR 0.36, SD 0.34, 95% CI: (0.1; 0.63)] at
the late follow-up visit. Comparing both groups, ICG did
not influence the functional outcome.
With regard to the morphological outcome, patients with
the use of ICG revealed a decrease of mean foveal thickness
from 483.94 μm (SD 112.4 μm, 95% CI: (442.02; 543.85)]
preoperatively to 347 μm [SD 116.85 μm, 95% CI: (284.74;
409.26)] at 3 months, to 347.06 μm [SD 128.51 μm, 95% CI:
(278.58; 415.54)] at 6 months and to 325 μm [SD 161.02 μm,
95% CI: (176.08; 473.92)] at the late follow-up visit. In
patients without the use of ICG the mean foveal thickness
preoperatively was 408.67 μm [SD 77.21 μm, 95% CI:
(349.31; 468.02)], at 3 months 299.4 μm [SD 80.35 μm, 95%
CI: (199.63; 399.17)], 197.5 μm [SD 53.65 μm, 95% CI:
(152.65; 242.35)] at 6 months and 235.63 μm [SD 74.6 μm,
95% CI: (173.26; 297.99)] at the late follow-up visit.
Hard exudates
Group I The numbers of hard exudates increased in 7/15
patients (46.66%), remained the same in 3/15
patients (20%) and decreased in 5/15 patients
(33.33%) at the 6-month visit in patients who
underwent posterior vitreous detachment only.
Group II The number of hard exudates increased in 6/18
patients (33%), remained the same in 2/18
patients (11%) and decreased in 10/18 patients
(56%) 6 months postoperatively when an addi-
tional ILM delamination was performed.
Group III In group III with preexisting PVD, the number of
hard exudates increased in 1/6 patients (16.5%),
remained the same in 1/6 patients (16.5%) and
decreased in 4/6 patients (67%) 6 months after
vitrectomy and ILM removal.ILM removal in
groups II and III was qualitatively found to
increase resorption rate of hard exudates.
Fluorescein angiography
Group I The extension of the edema enlarged in 5/19
patients (26.32%), remained unchanged in 6/19
patients (31.58%) and diminished in 8/19 patients
(42.11%) at 6 months. The intensity at that time
increased in 7/19 patients (36.84%), remained
unchanged in 1/19 patients (5.26%) and reduced
in 11/19 patients (57.89%). The foveolar avascular
zone (FAZ) had slightly enlarged in six patients
and decreased in one patient.
Group II The extension of the edema enlarged in 2/20
patients (10%), remained unchanged in 8/20
patients (40%) and decreased in 10/20 patients
(50%) at 6 months. The intensity at that time
increased in 3/20 patients (15%), remained
unchanged in 3/20 patients (15%) and reduced
in 14/20 patients (70%). In two patients the FAZ
slightly enlarged and diminished in three
patients. Comparing groups I and II, additional
ILM delamination did not qualitatively influ-
ence intensity or extension of edema.
Group III In group III with preexisting PVD, the
extension of edema enlarged in 1/11 patients
(9%), remained unchanged in 5/11 patients
(45.5%) and decreased in 5/11 patients
(45.5%) at 6 months. The intensity at that
time increased in 2/11 patients (18%),
remained unchanged in 2/11 patients (18%)
and decreased in 7/11 patients (64%). In one
patient the FAZ slightly enlarged, and in one
patient FAZ decreased.
Complications
Iatrogenic tears were observed intraoperatively in ten
patients (n=3 in group I, n=5 in group II, n=2 in group
III) and treated by cryocoagulation (n=10) and air (n=6) or
gas endotamponade (n=4).
Intraoperative iatrogenic opening or rupture of macular
cysts was not observed in any patient. In 42/44 (95.45%)
phakic patients, cataract formation with nuclear sclerosis
was observed within 6 months (n=15 in group I, n=19 in
group II, n=8 in group III).
Epiretinal membrane formation occured in one patient of
group I and in one patient of group II. One patient of group
II required re-vitrectomy and silicone oil tamponade for a
dense postoperative vitreous hemorrhage. In three patients,
a retinal detachment developed (group I: n=1, group II: n=
1, group III: n=1). These patients underwent successful
revitrectomy with encircling band (n=1), radial sponge (n=
2), and gas endotamponade (n=1).
Immunohistochemical results
ILMs of patients with diabetic maculopathy intensely
stained for bFGF and methylglyoxal-type AGEs (Fig. 4).
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In contrast, the glycoxidation marker CML was not
different when compared with ILMs from patients with
idiopathic macular holes. ILMs stained negatively for
VEGF, PDGF-B, TNFalpha and IL-6.
Discussion
Few data from randomized controlled trials are available
concerning the therapeutic effect of vitrectomy for diabetic
macular edema. Recently, Stolba et al. reported a favourable
outcome following vitrectomy and ILM peeling opposed to
the natural course [19]. Yanyali et al. also observed a
decrease in retinal thickness, without, however, significant
improvement of visual acuity [15]. Uncertainty exists as to
the necessity of ILM removal or whether PVD alone is
sufficient. In a retrospective study, Stefaniotou et al. found
that ILM peeling was beneficial in patients with diffuse
diabetic macular edema [24]. In contrast, Bahadir and
colleagues could not prove a beneficial effect of vitrectomy
and ILM removal in comparison to vitrectomy alone [25].
No significant improvement of functional results in patients
with diffuse diabetic macular edema was observed by Kumar
et al. comparing vitrectomy with removal of ILM in contrast
to grid laser photocoagulation [26].
The presented study provides the first randomized
controlled trial data demonstrating a favourable effect of
additional ILM removal in vitrectomy for cystoid diabetic
macular edema in diabetes type 2 patients without evident
vitreomacular traction, as shown in foveal thickness
measurements by OCT. In the long term, while PVD alone
slowly improves the anatomical results, it is markedly less
effective than additional ILM removal. Although, the
morphological results were substantial, visual results were
unsatisfactory. Comparing the results of groups I and II, it
can be stated that ILM removal shows the tendency of
being beneficial in eyes with primarily attached vitreous in
which a PVD was surgically induced analyzing the
secondary endpoint of foveal thickness. However, identifi-
cation of the posterior hyaloid by slit-lamp contact
biomicroscopy is notoriously difficult, and even OCT can
visualize the vitreoretinal interface only when it is partially
detached or where the PVD is located within a few
micrometers from the retinal surface. This was the reason
why the randomization was performed intraoperatively,
after a preexisting vitreous detachment was definitively
Fig. 4 Histologic section of a
surgically removed internal
limiting membrane from a
patient of group II showing
immunostainings for bFGF,
methylglyoxal-type AGE and
CML. Note that in comparison
with ILM from patients with
macular holes, there is no
difference in CML deposition,
but a substantial difference
for methylglyoxal-type AGE,
and, to a minor degree bFGF
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ruled out by the surgeon. In group I, the surgeon relied only
on the visualization of the Weiss ring during the PVD
induction, based on careful observation and surgical experi-
ence. No triamcinolone was used for the identification of
vitreous remnants, in order to exclude any influence of drug
remnants on the resorption of the macular edema. An incorrect
intraoperative judgement of the posterior vitreous may have
influenced the results. Even during surgery, it may be hard to
distinguish a PVD from vitreoschisis, especially in patients
with diabetic retinopathy. In those 20 eyes where ILM
removal was performed, it is extremely unlikely that the
posterior vitreous was still attached, especially in patients in
whom ICG was used for ILM removal, since dyes such as
ICG facilitate visualization of vitreous remnants.
Moreover, our results suggest that even when a
spontaneous PVD is present (group III), vitrectomy with
ILM removal may provide favourable morphological
results. It has to be emphasized that this group III was not
randomized, and that the number of included patients in all
groups was small. Due to this limiting drawback of the
present study, subgroup evaluation was complex, and the
conclusions must be looked at with caution. Nevertheless,
the study design was prospective.
The most distinct effect of our study seen on fluorescein
angiography was not in the decrease in edema size but
rather the reduction of staining intensity. This parameter is
difficult to quantify and OCT has become an important
tool, providing detailed morphologic information and
allowing the detection of macular edema with a sensitivity
of 89% and a specificity of 96% [1, 27, 28]. However, the
resolution available in OCT systems is not high enough to
distinguish between intra- and extracellular edema.
The exact pathomechanism of ILM removal on
diabetic macular edema is currently unknown. The
ILM, which is the basement membrane of the Müller
cells, may act as a diffusion barrier. Recent findings of a
comparative histopathological study of surgically re-
moved ILM showed that the ILMs in patients with
diabetic macular edema were significantly thicker (mean
thickness: 4.8±1.6 μm), revealing a larger amount of
cellular elements on the vitreous side than in patients
with macular holes (1.8±0.6 μm) [1, 29]. This thickened
ILM may act as a barrier, decreasing transretinal fluid
movement. After removal of this diffusion barrier, the
disturbance of transretinal fluid movement may be in part
restored and contribute to a resolution of the macular
edema [1]. Also, Radetzky et al. speculated about a
pseudomembrane formed by the endplates of Müller cells
exerting a barrier function [30]. Intraretinal structural
damage in chronic cystoid edema may further influence
the diffusion properties.
It is also possible that the thickened ILM may reduce the
diffusion of oxygen from the vitreous cavity to the retina
following vitrectomy. Stefánsson et al. have suggested that
fluid currents in the vitreous cavity following vitrectomy of
PVD transport oxygen from well-perfused areas of the retina
to hypoxic areas such as in diabetic macular edema [31, 32].
The diffusion of oxygen from the fluid in the vitreous cavity
into the retina would be retarded by a thickened ILM.
Another theory is that the repair mechanisms of Müller
cells may be activated by delamination of the ILM [33].
Also, the absence of the vitreous gel would increase the
transport of cytokines, such as VEGF, from the retina into
the vitreous cavity, and the absence of ILM would further
speed up this clearance of cytokines from the retina [8].
The efficacy of ILM delamination may be caused by the
removal of a growth factor reservoir which may have
accumulated in the ILM and in cellular elements on its
vitreous side. A recent study showed that vitreous remnants
may be present after surgical vitreous separation [34].
Histopathologic correlations by Gandorfer et al. [35] and
Matsunaga et al. [29] support the theory that ILM delami-
nation allows a more complete removal of vitreous elements.
As Fig. 4 demonstrates, CML and AGEs could be
detected within removed ILM specimens of patients with
diabetic macular edema of groups II and III, in contrast to
those gained during macular hole surgery. AGEs have been
implicated in the primary pathogenesis of diabetic vascular
damage that ultimately leads to progressive vascular
occlusions, as in diabetic maculopathy. Furthermore, AGEs
can enhance VEGF production and thereby induce perme-
ability changes. The finding of bFGF in the ILMs of
diabetic eyes supports previous data showing bFGF
deposits in the inner limiting membranes of retinae from
diabetic patients [36], and of experimentally diabetic
animals [37]. It is worth noting that bFGF is an important
repair/survival factor for retinal glia suggesting that our
finding is consistent with increased repair, rather than a sign
of damage. The glycoxidation product CML is present in a
variety of conditions associated with increased oxidative or
glycative stress, in particular in the eye [38–40]. The finding
that methylglyoxal-type AGE is found in membranes repre-
senting the endfeet of Müller cells is of particular clinical
interest, given the present debate concerning the role of
neuroglia in the course and pathogenesis of diabetic retinop-
athy, and the possible role of these specific AGEs in the link
between metabolic stress and transcriptional regulation of
genes in Müller cells [41]. AGEs can enhance VEGF
production, and thereby may induce permeability changes.
Compared to the promising anatomical findings, the
functional results in our study are less beneficial. The
additional ILM delamination still seemed to stabilize visual
acuity with an unchanged or better BCVA in 90% of
patients, despite development of a marked complicating
cataract in most patients within the follow-up period. There
was a statistically significant effect over time, revealing higher
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visual deterioration of BCVA in group I without ILM removal
[mean decrease of 0.19 logMAR, SD 0.27, 95%CI (0.06; 0.32
logMAR)] than in group II [mean decrease 0.05 logMAR, SD
0.14, 95% CI (−0.02;0.11)] but without treatment difference.
To rule out the influence of cataract formation at the end of the
study, we decided to additionally determine long-term visual
andmorphological results. This extension of the study was not
planned in the initial study protocol. Most of the patients had
undergone cataract extraction in the meantime, but surpris-
ingly there was no remarkable change among the groups.
Only group II showed improved VA results compared to
baseline; groups I and III remained stable.
Our limited functional results in group I stand in contrast
to recently published studies about vitrectomy without ILM
peeling in diabetic macular edema. La Heij et al. reported
on the resolution of diabetic macular edema in 21 of 21
eyes [11], and Tachi and Ogino in 57 of 58 eyes [13].
However, both studies based their findings on fluorescein
angiography and biomicroscopy, which makes an objective
measurement of retinal thickness difficult if not impossible.
Furthermore, the study results of La Heij are completely
based on follow-up examinations from referring ophthal-
mologists only, which raises doubt about the standardi-
zation of measurement conditions. Ikeda et al. performed
vitrectomy on three eyes of two patients in which
evidence of macular traction was specifically noted to
be absent. They observed resolution of macular edema
with improvement of visual acuity in all eyes [4]. In a
recent retrospective study, Rosenblatt et al. also reported
significant improvement of visual acuity and diminution
of retinal thickness in patients with refractory diabetic
macular edema without taut posterior hyaloid [18]. The
preexisting compromised retinal microvasculature in diabetic
eyes is likely to be more vulnerable to exsudation when
subjected to traction. Therefore, it is understandable that
vitrectomy and posterior vitreous separation was beneficial in
selected patients with diabetic macular edema when the
hyaloid has been judged to be taut [5, 7, 10]. However, the
patients in our study represent the typical situation in most
elderly diabetic mellitus type 2 patients where no clinically
visible vitreo-macular traction is present. Although there has
been a considerable number of studies implicating an
important role of the posterior hyaloid in the pathogenesis
of diabetic macular edema [11–13, 16], we did not find any
effect of posterior hyaloid detachment alone in our study.
One possible cause for the discrepancy of those studies in
comparison with our results is the longer history of macular
edema resulting in cystoid changes in a high number of
patients, and the selection of diabetic mellitus type 2 patients
in our patient series, which may have had a negative impact on
photoreceptor recovery in this elderly study population. The
presence of cystoid macular edema in our study population is
a clinical sign for the chronic nature of the edema and
longstanding intraretinal diabetic changes with irreversible
photoreceptor damage. Moreover, the limited functional
results in our study may have been influenced by bad systemic
glucose control (HbA1c: 7.59–8.15, see Table 1) [42].
Futhermore, visual outcome might have been adversely
affected by one or more prior grid laser photocoagulations,
treatment which was an inclusion criterion for our study.
During surgery in 11 patients, panretinal argon endolaser
coagulation due to severe non-proliferative or proliferative
diabetic retinopathy was performed, in ten patients
peripheral cryocoagulation and endotamponade for peripheral
iatrogenic tears. These findings had no statistical consequence
on functional or anatomic outcomes. However, as group sizes
are fairly small, we cannot rule out an additional impact.
Dillinger and Mester also observed a discrepancy between
the anatomical and functional outcome; however, they still
reported a significant visual improvement of 43%, gaining 2
lines of vision or more. In accordance with our positive results
in groups II and III, the authors reported a decrease in macular
thickening in 55 of 60 eyes after vitrectomy and ILM removal
in chronic diabetic macular edema [16]. Our study was
performed prospectively, but the quality of follow-up was
limited due to postoperative examinations by the referring
ophthalmologists and loss of standardized conditions.
Recently, in a prospective non-randomized study, Patel
et al. confirmed the beneficial effect of ILM removal on
morphological outcome, but also found limited visual
improvement [20]. They suspected that the normal Müller
cell physiology may be altered after ILM removal, which
may explain the lack of significant improvement in vision
despite a marked resolution of macular edema. We could
not show a significant effect of ILM removal; however, a
tendency towards improved results after PVD with
additional ILM removal could be seen.
Since ICG should allow a more complete ILM removal,
better morphological functional results could be expected in
the subgroup of patients in which it was used for staining.
However, in our study ICG seemed to affect visual and
morphological outcome negatively. Avci et al. reported about
spontaneous ILM detachment from the neurosensory retina
after ICG-assisted ILM peeling in patients with diabetic
macular edema, using 0.25 % ICG solution [43] for 1 minute
after total fluid–air exchange. We used a markedly lower
concentration of 0.05 % dissolved in glucose under constant
irrigation. But the observed tendency to poor results using
ICG corresponds with other reports on possible toxicity of
ICG. Brilliant Peel® was not available at that time.
The complication spectrum and rate is comparable to
other macular surgery studies, with a higher rate of retinal
tears and retinal detachments after surgically induced
posterior vitreous detachment.
In conclusion, our study underlines the efficacy of
PVD with additional ILM removal on resorption of
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cystoid diabetic macular edema, even without the
presence of vitreomacular traction. Improvement or at
least stabilization most likely can only be achieved when
the macular edema is reduced. A further visual deterio-
ration such as in group I is very likely if the macular
edema persists. A negative influence of ILM removal on
the visual outcome could not be proven by our data. The
procedure seemed to stabilize visual acuity, and therefore
this treatment option might be considered in earlier
stages of the disease to preserve vision at higher levels.
However, it has to be kept in mind that the study design
did not allow the assessment of the efficacy of
vitrectomy in diabetic macular edema against the natural
course or grid laser coagulation, which is the current
gold standard. Whether it is preferable to perform this
procedure as a first-line treatment for diffuse diabetic
macular edema instead of grid laser coagulation must be
evaluated in another trial. New treatment modalities such
as intravitreal triamcinolone acetonide [44–46] or anti-
VEGF drugs [47, 48] are promising, but recurrences and
the requirement of multiple re-injections are the major
backdraw of presently available drugs. As our late analysis
suggests, vitrectomy and ILM removal is able to stabilize
visual and morphological results also on the longterm.
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